source · text/markdown
source_70a7a3b7b38b4f5f
sha256 1ba8310bf2b61a66fdeb7f35829e7b6180c2ebd0603a825a800bdc37ce17d288
by researka:v2 · 2026-06-22 14:14:52.702227+04:00
# Source literature boundary memo ## Research question What does the selected source bundle show about the evidence boundary for fisetin? ## Selection criteria The latest Longevity / anti-aging research discovery pass ranked fisetin as source-rich. The fallback requires at least five verifiable source papers, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy. ## Boundary map - Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence [primary; 2023] doi:10.1111/acel.14060 - Improving solubility of fisetin by cocrystallization [primary; 2014] doi:10.1039/c4ce01713g - Fisetin Protects PC12 Cells from Tunicamycin-Mediated Cell Death via Reactive Oxygen Species Scavenging and Modulation of Nrf2-Driven Gene Expression, SIRT1 and MAPK Signaling in PC12 Cells [primary; 2017] doi:10.3390/ijms18040852 - Antiproliferative Mechanisms of the Flavonoids 2,2′-Dihydroxychalcone and Fisetin in Human Prostate Cancer Cells [primary; 2010] doi:10.1080/01635581003605524 - Senolytic elimination of senescent macrophages restores muscle stem cell function in severely dystrophic muscle [primary; 2022] doi:10.18632/aging.204275 ## Source synthesis Answer: this 5-source primary bundle supports a conventional scoping note for fisetin, spanning undated. The bounded signal is source-frontier separation: these papers can define what must be checked next, but they do not establish a causal, clinical, species-translated, or mechanistically integrated intervention claim. ## Boundary limits Source-literature boundary for fisetin: the listed sources define separate evidence fronts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. ## Next gaps Before promotion to a causal alpha memo, a future run needs receipt-level agreement on population, exposure or intervention, comparator, endpoint, and species context.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "171b0392-7da0-450b-bd30-d81fa4f4a4af",
"title": "fisetin source-literature boundary"
}